Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine vs Placebo in Children with ADHD and Comorbid ODD
NCT00191698Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2003
- Primary completion
- Jun 2005
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in oppositional defiant disorder (ODD) comparing Atomoxetine with Placebo (2 arms). Primary endpoint: Swanson, Nolan and Pelham Rating Scale-Revised (SNAP-IV) ODD Symptoms at 8 weeks. Started Dec 2003; status: completed.
02
Drugs
atomoxetine
03
Conditions
oppositional defiant disorder (ODD)
Beyond the preview
Go deeper on NCT00191698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00191698.